Karyopharm Therapeutics Inc. Human Resources Contracts & Agreements
41 Contracts & Agreements
- Bonus & Incentive Agreements (21 contracts)
- Compensation Agreements (3)
- Consulting Agreements (10)
- Retention Agreements (1)
- Separation Agreements (1)
- Severance Agreements (2)
- Transition Agreements (3)
- Non-Employee Director Compensation Policy (Filed With SEC on May 8, 2024)
- Karyopharm Therapeutics Inc. Annual Bonus Plan (Filed With SEC on February 29, 2024)
- Karyopharm Therapeutics Inc. Annual Bonus Plan (Filed With SEC on August 2, 2023)
- Form of Restricted Stock Unit Agreement (Performance Vested) under 2022 Equity Incentive Plan (Filed With SEC on February 15, 2023)
- Consulting Agreement, dated August 2, 2022, between the Registrant and Ran Frenkel (Filed With SEC on August 4, 2022)
- Severance agreement, dated August 2, 2022, between the Registrant and Ran Frenkel (Filed With SEC on August 4, 2022)
- Non-Employee Director Compensation Policy dated June 30, 2022 (Filed With SEC on August 4, 2022)
- Form of Restricted Stock Unit Agreement under the 2022 Israel Equity Incentive Sub Plan to the 2022 Equity Incentive Plan (Filed With SEC on August 4, 2022)
- Form of Incentive Stock Option Agreement under the 2022 Israeli Equity Incentive Sub Plan to the 2022 Equity Incentive Plan (Filed With SEC on August 4, 2022)
- Form of Restricted Stock Unit Agreement under 2022 Equity Incentive Plan (Filed With SEC on August 4, 2022)
- Form of Incentive Stock Option Agreement under 2022 Equity Incentive Plan (Filed With SEC on August 4, 2022)
- Amendment #1 to Consulting Agreement, dated March 21, 2022, between the Registrant and Jatin Shah (Filed With SEC on May 5, 2022)
- Consulting Agreement, dated March 1, 2022, between the Registrant and Jatin Shah (Filed With SEC on May 5, 2022)
- Severance Agreement, dated February 18, 2022, between the Registrant and Jatin Shah (Filed With SEC on May 5, 2022)
- Transition Agreement, dated March 28, 2022, between the Company and Sharon Shacham (Filed With SEC on March 29, 2022)
- Transition Agreement, dated March 28, 2022, between the Company and Michael G. Kauffman (Filed With SEC on March 29, 2022)
- Form of Restricted Stock Unit Agreement under 2022 Inducement Stock Incentive Plan (Filed With SEC on March 1, 2022)
- Form of Nonstatutory Stock Option Agreement under 2022 Inducement Stock Incentive Plan (Filed With SEC on March 1, 2022)
- 2022 Inducement Stock Incentive Plan (Filed With SEC on March 1, 2022)
- Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan adopted January 24, 2022 (Filed With SEC on March 1, 2022)
- Non-Employee Director Compensation Policy, dated as of May 12, 2021 (Filed With SEC on August 5, 2021)
- Form of Restricted Stock Unit Agreement under 2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan (Filed With SEC on November 2, 2020)
- Form of Option Agreement under 2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan (Filed With SEC on November 2, 2020)
- 2020 Israeli Equity Incentive Sub Plan to the 2013 Stock Incentive Plan (Filed With SEC on November 2, 2020)
- Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan adopted August 25, 2020 (Filed With SEC on November 2, 2020)
- Form of Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan adopted August 25, 2020 (Filed With SEC on November 2, 2020)
- Form of Incentive Stock Option Agreement under 2013 Stock Incentive Plan adopted August 25, 2020 (Filed With SEC on November 2, 2020)
- Consulting Agreement, dated as of September 25, 2020, between the Company and Christopher B. Primiano (Filed With SEC on September 25, 2020)
- Transition Agreement, dated as of September 25, 2020, between the Company and Christopher B. Primiano (Filed With SEC on September 25, 2020)
- Karyopharm Therapeutics Inc. Annual Bonus Plan (Filed With SEC on August 6, 2019)
- Retention Agreement dated January 17, 2019, between the Company and Cameron Peters (Filed With SEC on January 18, 2019)
- Consulting Agreement dated January 18, 2019, between the Company and Michael Falvey (Filed With SEC on January 18, 2019)
- Separation Agreement dated January 17, 2019, between the Company and Michael Falvey (Filed With SEC on January 18, 2019)
- CONSULTING AGREEMENT (Filed With SEC on April 3, 2017)
- FIRST AMENDMENT TO CONSULTING AGREEMENT BETWEEN KARYOPHARMTHERAPEUTICS AND MIRZA CONSULTING (Filed With SEC on November 9, 2015)
- CONSULTING AGREEMENT (Filed With SEC on August 8, 2014)
- KARYOPHARM THERAPEUTICS INC. INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on October 28, 2013)
- KARYOPHARM THERAPEUTICS INC. 2013 STOCK INCENTIVE PLAN (Filed With SEC on October 28, 2013)
- CONSULTING AGREEMENT (Filed With SEC on October 4, 2013)
- Consulting Agreement (Filed With SEC on October 4, 2013)
